Eric brings approximately 25 years of experience in the healthcare industry focusing on clinical development, value demonstration, market access, and commercial optimzation. At Evidera, he focuses on health technologies with significant disruptive potential such as cell and gene therapies, precision medicine, diagnostics, orphan disease, and medical and e-connective technologies.
Eric is a recognized global thought leader in emerging technology market access, with extensive publication and over 100 global panel sessions spanning North America, Europe and Asia. He currently serves on Leadership Committee for Value Demonstration and Market Access for the Alliance for Regenerative Medicine (ARM) and the Business Models and Reimbursement Committee for the International Society for Cell and Gene Therapy (ISCT), as well as the Executive Steering Committee for the ARM Foundation. He also serves on the Leadership Committees for Precision and Advanced Therapies (former inaugural Chair) and Medical Devices and Diagnostics Special Interest Groups for the International Society for Pharmacoeconomics an Outcomes Research (ISPOR). He has also served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology, the Duke Margolis Institute, MIT NEWDIGS, the Oncotyrol Center for Precision Cancer Medicine in Austria and branches of the US Department for Health and Human Services (HHS).
Mr. Faulkner has also served for over 15 years as the Executive Director of the Genomics Biotech and Emerging Medical Technology Institute of the National Association of Managed Care Physicians (NAMCP), including >100 US commercial payers and >40 life science manufacturers. Eric also serves as an Adjunct Assistant Professor for the Eshelman School of Pharmacy for the University of North Carolina at Chapel Hill.